Journal of Pharmacy And Bioallied Sciences
Journal of Pharmacy And Bioallied Sciences Login  | Users Online: 2091  Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size 
    Home | About us | Editorial board | Search | Ahead of print | Current Issue | Past Issues | Instructions | Online submission

    Article Cited by others


Fingolimod: The first oral drug approved by food and drug administration; A breakthrough in treatment of multiple sclerosis

Singh Manish, Cugati Goutham, Singh Pratibha, Singh Ajai Kumar

Year : 2011| Volume: 3| Issue : 3 | Page no: 460-461

   This article has been cited by
1 Identification of Potential Inhibitors against Epstein–Barr Virus Nuclear Antigen 1 (EBNA1): An Insight from Docking and Molecular Dynamic Simulations
Shweta Jakhmola, Nisha Amarnath Jonniya, Md Fulbabu Sk, Annu Rani, Parimal Kar, Hem Chandra Jha
ACS Chemical Neuroscience. 2021; 12(16): 3060
[Pubmed]  [Google Scholar] [DOI]
2 Update on disease-modifying therapies for multiple sclerosis
Diana L Vargas,William R Tyor
Journal of Investigative Medicine. 2017; 65(5): 883
[Pubmed]  [Google Scholar] [DOI]
3 Signalling by protein phosphatases and drug development: A systems-centred view
Nguyen, L.K. and Matallanas, D. and Croucher, D.R. and Von Kriegsheim, A. and Kholodenko, B.N.
FEBS Journal. 2013; 280(2): 751-765
[Pubmed]  [Google Scholar]
4 Signalling by protein phosphatases and drug development: a systems-centred view
Lan K. Nguyen,David Matallanas,David R. Croucher,Alexander von Kriegsheim,Boris N. Kholodenko
FEBS Journal. 2013; 280(2): 751
[Pubmed]  [Google Scholar] [DOI]


Read this article